Current partner codePEPTIDESDE
NCT05564039·Phase 4·INTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Status

Completed

Phase

Phase 4

Enrollment

282

Locations

38

Results

Posted

Publications

2

Study summary

What the protocol is testing.

The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.

Interventions

Treatment arms and agents.

DRUG

Tirzepatide

Administered SC

DRUG

Dulaglutide

Administered SC

Timeline

From registration to results.

  1. First posted

    Oct 3, 2022

  2. Study start

    Nov 30, 2022

  3. Primary completion

    Jul 15, 2024

  4. Study completion

    Aug 12, 2024

  5. Results posted

    Aug 3, 2025

  6. Registry updated

    Aug 3, 2025

Outcomes

What the study measures.

Primary outcomes

Change From Baseline in HbA1c

Time frame · Baseline, Week 40

HbA1c is the glycated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Secondary outcomes

Change From Baseline in Body Weight

Time frame · Baseline, Week 40

LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Percentage of Participants Who Achieved HbA1c <7%

Time frame · Week 40

The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing endpoint measures are imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for Baseline HbA1c Value, Baseline SGLT2i use(Yes/No), Treatment, Visit, and Treatment by Visit interaction.

Percentage of Participants Who Achieved HbA1c <=6.5%

Time frame · Week 40

The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Logistic regression model was used with missing endpoint measures imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for baseline HbA1c, geographic region 1, number of background OAMs in group 1, dulaglutide dose at screening, and treatment as factors.

Percentage of Participants Who Achieved HbA1c <5.7%

Time frame · Week 40

The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Logistic regression model was used with missing endpoint measures imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for baseline HbA1c, geographic region 1, number of background OAMs in group 1, dulaglutide dose at screening, and treatment as factors.

Percentage of Participants Who Achieve Weight Loss From Baseline of ≥5%

Time frame · Week 40

Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

Percentage of Participants Who Achieve Weight Loss From Baseline of ≥10%

Time frame · Week 40

Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

Percentage of Participants Who Achieve Weight Loss From Baseline of ≥15%

Time frame · Week 40

Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5% & Weight Loss >=10% & No-Hypoglycemia)

Time frame · Week 40

A composite endpoint is defined as HbA1c ≤ 6.5%, weight loss ≥ 10%, and no hypoglycemia, defined as blood glucose (BG) \<3.0 millimole/liter (mmol/L) and/or severe hypoglycemia. Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: For HbA1c: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Treatment + Time + Treatment\*Time. For Weight: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HbA1c Group + Treatment + Time + Treatment\*Time.

Change From Baseline in Fasting Serum Glucose (FSG)

Time frame · Baseline, Week 40

LSMean was calculated using the ANCOVA model for endpoint measures: Variable = Baseline + A1CGR1 + DULDSCRN + OAMGR1 + REGION1 + Treatment (Type I sum of squares).

Change From Baseline in Waist Circumference

Time frame · Baseline, Week 40

LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Have type 2 diabetes * Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol) * Are currently on a stable dose of dulaglutide weekly (0.75 mg or 1.5 mg) for at least 6 months prior to screening. * No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of up to 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening. * Have had stable body weight (±5%) during the 90 days preceding screening * Have BMI ≥25 kilogram/square meter (kg/m²) Exclusion Criteria: * Have type 1 diabetes * Have a history of chronic or acute pancreatitis * Have a history of * proliferative diabetic retinopathy, or * diabetic maculopathy, or * nonproliferative diabetic retinopathy that requires acute treatment. * Have any of these cardiovascular (CV) conditions within 60 days prior to screening: * acute myocardial infarction, * cerebrovascular accident (stroke), or * hospitalization due to congestive heart failure (CHF). * Have New York Heart Assocation (NYHA) Functional Classification Class IV CHF * Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). * Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over-the-counter, or alternative remedies * Have an estimated glomerular filtration rate (eGFR) \<30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label) * Have been treated with insulin prior to screening * Exception: use of insulin for gestational diabetes or short-term use (\<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery. * Have a history of reduction of dose of dulaglutide, due to intolerability, without successful reescalation

Study locations

38 registered sites.

Belgium · Germany · Mexico · Romania · United States. Showing up to 24 locations stored in the fast local snapshot.

ALL Medical Research, LLC

Cooper City, Florida, United States

Metabolic Research Institute, Inc.

West Palm Beach, Florida, United States

NorthShore University Health System

Skokie, Illinois, United States

Iowa Diabetes and Endocrinology Research Center

West Des Moines, Iowa, United States

Clinvest Research LLC

Springfield, Missouri, United States

Alliance for Multispecialty Research, LLC

Norman, Oklahoma, United States

Juno Research

Houston, Texas, United States

Biopharma Informatic, LLC

Houston, Texas, United States

Juno Research

Houston, Texas, United States

Southern Endocrinology Associates

Mesquite, Texas, United States

North Hills Family Medicine/North Hills Medical Research

North Richland Hills, Texas, United States

Imelda General Hospital

Bonheiden, Antwerpen, Belgium

Antwerp University Hospital

Edegem, Antwerpen, Belgium

ZNA Jan Palfijn

Merksem, Flanders, Belgium

AZ Nikolaas

Sint-Niklaas, Oost-Vlaanderen, Belgium

UZ Leuven

Leuven, Vlaams-Brabant, Belgium

Az Damiaan vzw

Ostend, West-Vlaanderen, Belgium

InnoDiab Forschung Gmbh

Essen, North Rhine-Westphalia, Germany

Institut für Diabetesforschung GmbH Münster

Münster, North Rhine-Westphalia, Germany

Studienzentrum Dr. Tasso Bieler

Riesa, Saxony, Germany

RED-Institut GmbH

Oldenburg in Holstein, Schleswig-Holstein, Germany

Medizinisches Versorgungszentrum am Bahnhof Spandau

Spandau, State of Berlin, Germany

Diabeteszentrum Hamburg West

Hamburg, Germany

Diseno y Planeacion en Investigacion Medica

Guadalajara, Jalisco, Mexico

Related trials

More studies on Dulaglutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.